| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8653260 | UROVANT | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
Apr, 2029
(5 years from now) | |
| US8247415 | UROVANT | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2030
(7 years from now) | |
Gemtesa is owned by Urovant.
Gemtesa contains Vibegron.
Gemtesa has a total of 2 drug patents out of which 0 drug patents have expired.
Gemtesa was authorised for market use on 23 December, 2020.
Gemtesa is available in tablet;oral dosage forms.
Gemtesa can be used as treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Drug patent challenges can be filed against Gemtesa from 2024-12-23.
The generics of Gemtesa are possible to be released after 01 December, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 23, 2025 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 2024-12-23
Market Authorisation Date: 23 December, 2020
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Dosage: TABLET;ORAL
GEMTESA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic